Additionally, ARID1A deficiency is associated with a reduced mismatch repair (MMR) capacity and increased cancer mutability to recruit infiltrating immune cells, increasing the therapeutic efficacy of ICBs [12, 13]. The gene discussed is ARID1A; the disease is cancer.